Who to call at Alzamend Neuro, Inc., and when
Fundz watches for the moments Alzamend Neuro, Inc. starts buying, and tells you who to reach.
- An alert the day Alzamend Neuro, Inc. raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Alzamend Neuro, Inc., from your own LinkedIn network
Alzamend Neuro, Inc.
The company shared information publicly (Regulation FD). An 8-K is the notice a US public company must file within four business days of a major event.
alzamendrega.comAI Executive Summary
AI-powered analysis of 8-K filing content
Dr. Ovidiu C. Andronesi, principal investigator for Alzamend Neuro's Phase 1/2A clinical trial, presented findings at the ISMRT Conference on September 29, 2026, demonstrating progress in the company's neurological research and strengthening relationships with medical professionals.
Key Takeaways
Clinical trial data was presented at a major international medical conference, signaling advancement in Alzamend's neurological research program
The presentation by the principal investigator demonstrates the company's research capabilities to the medical and scientific community
1 more takeaway
Related Filings (2)
2 more filings from Alzamend Neuro, Inc. in the last 90 days
Filing Overview
What This Means
Alzamend Neuro, Inc. filed with the SEC. Fundz turns 8-K material events into an alert with the right executive attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
4 screens from a live account. No signup.